DINAMIQS gets Swissmedic approval for cGMP viral vector production

DINAMIQS, a Siegfried company, has received a manufacturing and testing license from Swissmedic for viral vector cGMP production, authorizing the CDMO to manufacture and release ATMPs under GMP conditions.

The license establishes DINAMIQS as the first fully integrated viral vector CDMO in Switzerland offering end-to-end capabilities from process development to drug product fill and finish, all within a single facility. Located in Zurich, the company’s 2,500 m² cGMP facility is purpose-built for viral vector manufacturing at scales of up to 1,000L.

Switzerland’s mutual recognition agreements with both the EMA and the U.S. FDA mean that products manufactured under Swissmedic oversight benefit from streamlined acceptance pathways across Europe and the United States.

DINAMIQS was spun out of Swiss biotech company builder DINAQOR in 2022 and acquired a year later by Swiss CDMO Siegfried.